U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H22N2.2C4H4O4
Molecular Weight 522.5464
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of AZATADINE MALEATE

SMILES

OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.CN1CCC(CC1)=C2C3=C(CCC4=C2N=CC=C4)C=CC=C3

InChI

InChIKey=SGHXFFAHXTZRQM-SPIKMXEPSA-N
InChI=1S/C20H22N2.2C4H4O4/c1-22-13-10-16(11-14-22)19-18-7-3-2-5-15(18)8-9-17-6-4-12-21-20(17)19;2*5-3(6)1-2-4(7)8/h2-7,12H,8-11,13-14H2,1H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-

HIDE SMILES / InChI

Molecular Formula C20H22N2
Molecular Weight 290.4021
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Azatadine is an antihistamine, which blocks the effects of the naturally occurring chemical histamine in the body. Azatadine is used to treat sneezing; runny nose; itching, watery eyes; hives; rashes; and other symptoms of allergies and the common cold. The antihistamines antagonize those pharmacological effects of histamine, which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
OPTIMINE

Approved Use

Azatadine is used to treat sneezing; runny nose; itching, watery eyes; hives; rashes; itching; and other symptoms of allergies and the common cold.

Launch Date

2.28441604E11
Palliative
OPTIMINE

Approved Use

Azatadine is used to treat sneezing; runny nose; itching, watery eyes; hives; rashes; itching; and other symptoms of allergies and the common cold.

Launch Date

2.28441604E11
Palliative
OPTIMINE

Approved Use

Azatadine is used to treat sneezing; runny nose; itching, watery eyes; hives; rashes; itching; and other symptoms of allergies and the common cold.

Launch Date

2.28441604E11
Palliative
OPTIMINE

Approved Use

Azatadine is used to treat sneezing; runny nose; itching, watery eyes; hives; rashes; itching; and other symptoms of allergies and the common cold.

Launch Date

2.28441604E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.4 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AZATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
20.5 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AZATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.9 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AZATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
8 mg 1 times / day multiple, oral
Highest studied dose
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
healthy, 18-25 years
n = 32
Health Status: healthy
Age Group: 18-25 years
Sex: M
Population Size: 32
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

PubMed

PubMed

TitleDatePubMed
Peripheral antihistamine and central sedative effects of three H1-receptor antagonists.
1985
Demonstration of inhibition of mediator release from human mast cells by azatadine base. In vivo and in vitro evaluation.
1986 Jan 10
"In vivo" and "in vitro" evaluation of four antihistamines (astemizole, azatadine, mequitazine, terfenadine).
1989 Mar-Apr
Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis.
1990 Dec
Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation.
1990 Feb
The effect of antihistamines on the immediate allergic response: a comparative review.
1993 Jun
Fungal biotransformation of the antihistamine azatadine by Cunninghamella elegans.
1996 Sep
Antiallergic effects of H1-receptor antagonists.
2000
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures.
2001 Apr
Quantitation of antihistamines in pharmaceutical preparations by liquid chromatography with a micellar mobile phase of sodium dodecyl sulfate and pentanol.
2001 Nov-Dec
Antiallergic anti-inflammatory effects of H1-antihistamines in humans.
2002
Antihistamines in the treatment of dermatitis.
2003 Nov-Dec
The use of antiserotonin drugs in the nucleoreticular vestibular syndrome: preliminary observations.
2004
Syntheses of molecularly imprinted polymers: Molecular recognition of cyproheptadine using original print molecules and azatadine as dummy templates.
2009 Jan 12
Application of dummy molecularly imprinted solid-phase extraction in the analysis of cyproheptadine in bovine urine.
2009 May
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Patents

Patents

Sample Use Guides

In Vivo Use Guide
The maximum amount of azatadine that you should take in 1 day is 2 mg. Azatadine can be taken with or without food.
Route of Administration: Oral
In Vitro Use Guide
Azatadine 0.1-10 uM significantly and dose dependently inhibited the release of leukotrienes from lung by 22-71%. Histamine release was also inhibited by azatadine 10 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:08:36 UTC 2023
Edited
by admin
on Fri Dec 15 15:08:36 UTC 2023
Record UNII
F3Q391WTX7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AZATADINE MALEATE
MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
Azatadine maleate [WHO-DD]
Common Name English
AZATADINE DIMALEATE [MI]
Common Name English
AZATADINE MALEATE [USAN]
Common Name English
AZATADINE MALEATE [VANDF]
Common Name English
AZATADINE MALEATE [JAN]
Common Name English
SCH 10649
Code English
AZATADINE MALEATE [USP IMPURITY]
Common Name English
OPTIMINE
Brand Name English
AZATADINE MALEATE [ORANGE BOOK]
Common Name English
NSC-759874
Code English
AZATADINE MALEATE [MART.]
Common Name English
5H-BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE, 6,11-DIHYDRO-11-(1-METHYL-4-PIPERIDINYLIDENE)-, (Z)-2-BUTENEDIOATE (1:2)
Systematic Name English
6,11-Dihydro-11-(1-methyl-4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine maleate (1:2)
Systematic Name English
TRINALIN COMPONENT AZATADINE MALEATE
Common Name English
AZATADINE MALEATE COMPONENT OF TRINALIN
Common Name English
SCH-10649
Code English
AZATADINE DIMALEATE
MI  
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29578
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
Code System Code Type Description
MERCK INDEX
m2164
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
PRIMARY Merck Index
EPA CompTox
DTXSID301027735
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
PRIMARY
CAS
3978-86-7
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
PRIMARY
DRUG BANK
DBSALT000973
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
PRIMARY
ChEMBL
CHEMBL946
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
PRIMARY
ECHA (EC/EINECS)
223-615-8
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
PRIMARY
RXCUI
58275
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
PRIMARY RxNorm
NCI_THESAURUS
C61642
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
PRIMARY
SMS_ID
100000084967
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
PRIMARY
PUBCHEM
5281066
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
PRIMARY
CHEBI
2947
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
PRIMARY
EVMPD
SUB00640MIG
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
PRIMARY
FDA UNII
F3Q391WTX7
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
PRIMARY
NSC
759874
Created by admin on Fri Dec 15 15:08:36 UTC 2023 , Edited by admin on Fri Dec 15 15:08:36 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY